Beda Jean-Francois
$656,157
University of Washington
Washington
National Center for Complementary and Integrative Health (NCCIH)
Post-acute sequelae of COVID-19 (PASC), or “Long-COVID” has negatively impacted millions of individuals with regard to quality of life, daily functioning, and ability to work, and has placed enormous demands on the healthcare system. Pain-related symptoms are reported by almost half of all patients with PASC, and yet pain is still not consistently addressed in work-ups or treatment options. Thus, we have chosen to study acupuncture for improving pain, quality of life, and function in individuals experiencing PASC-related pain. These treatments have been successful in treating various types of chronic pain and should lend themselves to similar results with PASC-related pain. Furthermore, acupuncture focuses on treating the whole patient, which makes it uniquely well-suited for a complex condition like PASC that affects multiple body systems. We propose an initial study to determine the feasibility of successfully conducting a subsequent fully-powered pragmatic randomized trial evaluating the effectiveness of Traditional Chinese Medicine acupuncture for persistent pain problems experienced by persons with PASC. Acupuncture is a physical treatment that aims to correct imbalances in the body (including inflammation and pain) within a Chinese Medicine paradigm. This study will occur through the University of Washington Post-COVID Rehabilitation and Recovery Clinic at the Northgate Primary Care Clinic site. Our specific aims are to (1) assess the feasibility of conducting a randomized clinical trial comparing acupuncture with usual care alone for reducing pain in patients with PASC; (2) evaluate the overall patient experience with participation in the feasibility trial and solicit suggestions about how the study procedures, documents, and treatment protocols could be improved to facilitate participation and better meet participants’ needs; and (3) revise study procedures, protocols, and instruments to prepare for a fully-powered pragmatic randomized trial. Our study is innovative because it focuses on treatments that address whole person health rather than individual symptoms. We believe whole-person-oriented treatments can improve outcomes for patients with PASC when used as adjuncts to usual medical care. This study has the potential to help patients with PASC improve function and quality of life, and to provide PASC clinicians with more tools to effectively respond to their patients’ needs.